BTK and B-cell chronic lymphocytic leukemia: Next, we aimed to investigate whether common targeted therapies for CLL, specifically those that inhibit BTK (e.g., ibrutinib) or BCL2 (e.g., venetoclax), exert effects through the induction of ferroptosis.